Yeu-Yao Cheng1,2, Jack Nunn3, John Skinner1, Boe Rambaldini1, Tiffany Boughtwood4,5, Tom Calma1, Alex Brown6, Cliff Meldrum7, Marcel E Dinger8, Jennifer A Byrne9,10, Debbie McCowen11, Jayden Potter11, Kerry Faires11, Sandra Cooper12,13,14, Kylie Gwynne1,15. 1. Poche Centre for Indigenous Health, The University of Sydney, Camperdown, NSW 2050, Australia. 2. Faculty of Medicine and Health, The University of Sydney School of Medicine, Camperdown, NSW 2050, Australia. 3. School of Psychology and Public Health, La Trobe University, Melbourne, VIC 3086, Australia. 4. Australian Genomics Health Alliance, Melbourne, VIC 3052, Australia. 5. Murdoch Children's Research Institute, Melbourne, VIC 3052, Australia. 6. South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia. 7. NSW Health Pathology, Sydney, NSW 2065, Australia. 8. School of Biotechnology and Biomolecular Sciences, UNSW, Sydney, NSW 2052, Australia. 9. New South Wales Health Statewide Biobank, New South Wales Health Pathology, Camperdown, NSW 2050, Australia. 10. School of Medical Sciences, Faulty of Medicine and Health, The University of Sydney, Camperdown, NSW 2006, Australia. 11. Armajun Aboriginal Health Service, 1 Rivers Street, Inverell, NSW 2360, Australia. 12. Kids Neuroscience Centre, Children's Hospital at Westmead, Westmead, NSW 2145, Australia. 13. Discipline of Child and Adolescent Health, The University of Sydney, Camperdown, NSW 2006, Australia. 14. The Children's Medical Research Institute, Westmead, NSW 2145, Australia. 15. Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW 2113, Australia.
Abstract
(1) Background: Genomic precision medicine (PM) utilises people's genomic data to inform the delivery of preventive and therapeutic health care. PM has not been well-established for use with people of Aboriginal and Torres Strait Islander ancestry due to the paucity of genomic data from these communities. We report the development of a new protocol using co-design methods to enhance the potential use of PM for Aboriginal Australians. (2) Methods: This iterative qualitative study consists of five main phases. Phase-I will ensure appropriate governance of the project and establishment of a Project Advisory Committee. Following an initial consultation with the Aboriginal community, Phase-II will invite community members to participate in co-design workshops. In Phase-III, the Chief Investigators will participate in co-design workshops and document generated ideas. The notes shall be analysed thematically in Phase-IV with Aboriginal community representatives, and the summary will be disseminated to the communities. In Phase-V, we will evaluate the co-design process and adapt our protocol for the use in partnership with other communities. (3) Discussion: This study protocol represents a crucial first step to ensure that PM research is relevant and acceptable to Aboriginal Australians. Without fair access to PM, the gap in health outcome between Aboriginal and non-Aboriginal Australians will continue to widen.
(1) Background: Genomic precision medicine (PM) utilises people's genomic data to inform the delivery of preventive and therapeutic health care. PM has not been well-established for use with people of Aboriginal and Torres Strait Islander ancestry due to the paucity of genomic data from these communities. We report the development of a new protocol using co-design methods to enhance the potential use of PM for Aboriginal Australians. (2) Methods: This iterative qualitative study consists of five main phases. Phase-I will ensure appropriate governance of the project and establishment of a Project Advisory Committee. Following an initial consultation with the Aboriginal community, Phase-II will invite community members to participate in co-design workshops. In Phase-III, the Chief Investigators will participate in co-design workshops and document generated ideas. The notes shall be analysed thematically in Phase-IV with Aboriginal community representatives, and the summary will be disseminated to the communities. In Phase-V, we will evaluate the co-design process and adapt our protocol for the use in partnership with other communities. (3) Discussion: This study protocol represents a crucial first step to ensure that PM research is relevant and acceptable to Aboriginal Australians. Without fair access to PM, the gap in health outcome between Aboriginal and non-Aboriginal Australians will continue to widen.
Entities:
Keywords:
Aboriginal and Torres Strait Islanders; Aboriginal health; Australian; co-design; genomics; participatory research; personalised medicine; precision medicine
Authors: Jack S Nunn; Thomas Shafee; Steven Chang; Richard Stephens; Jim Elliott; Sandy Oliver; Denny John; Maureen Smith; Neil Orr; Jennifer Preston; Josephine Borthwick; Thijs van Vlijmen; James Ansell; Francois Houyez; Maria Sharmila Alina de Sousa; Roan D Plotz; Jessica L Oliver; Yaela Golumbic; Rona Macniven; Samuel Wines; Ann Borda; Håkon da Silva Hyldmo; Pen-Yuan Hsing; Lena Denis; Carolyn Thompson Journal: Res Involv Engagem Date: 2022-07-19
Authors: Sid Kaladharan; Miranda E Vidgen; John V Pearson; Victoria K Donoghue; David C Whiteman; Nicola Waddell; Gregory Pratt Journal: BMJ Glob Health Date: 2021-11